After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
Tiny biotech Aurinia Pharmaceuticals is looking to slay a giant in GlaxoSmithKline’s Benlysta — which just scored a big approval in lupus nephritis — with its late-stage voclosporin on the cusp of an FDA approval. Looking to take its commercial plans global, Aurinia has tapped a Japanese pharma to accelerate its potential voclosporin launch.
Aurinia will hand over licensing rights for lupus nephritis candidate voclosporin in the EU, Japan and elsewhere to Otsuka Pharmaceutical as the late-stage drug rapidly approaches its FDA review date, the companies said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.